<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; IPR</title>
	<atom:link href="http://www.tapanray.in/tag/ipr/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Making New Cancer Drugs Cost-effective</title>
		<link>http://www.tapanray.in/making-new-cancer-drugs-cost-effective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=making-new-cancer-drugs-cost-effective</link>
		<comments>http://www.tapanray.in/making-new-cancer-drugs-cost-effective/#comments</comments>
		<pubDate>Mon, 17 Apr 2017 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[cost-effective]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repositioning]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[Sildenefil]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thalidomide]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[viagra]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8188</guid>
		<description><![CDATA[The prices of new cancer drugs are increasingly becoming unsustainable across the world, and more so in India. A sizable number of poor and even middle-income patients, who spend their entire life’s savings for the treatment of this dreaded disease, &#8230; <a href="http://www.tapanray.in/making-new-cancer-drugs-cost-effective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/making-new-cancer-drugs-cost-effective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>At The Indian IPR Front: ‘Ground Control, There’s No Major Storm’</title>
		<link>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=at-the-indian-ipr-front-ground-control-theres-no-major-storm</link>
		<comments>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/#comments</comments>
		<pubDate>Mon, 05 Sep 2016 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[2016 Special 301 Report]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[4-5]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[G 20]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[September]]></category>
		<category><![CDATA[Sherpa]]></category>
		<category><![CDATA[storm]]></category>
		<category><![CDATA[Summit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USIBC]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7794</guid>
		<description><![CDATA[The incessant pressure of the developing countries on India, from 2005 to date, to include various restrictive conditions in the Indian Patents Act 2005, still continue. This demand spans across the inclusion of even those provisions, which many experts term &#8230; <a href="http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Patents Act To Prevail Undiluted…Finally</title>
		<link>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-patents-act-to-prevail-undilutedfinally</link>
		<comments>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/#comments</comments>
		<pubDate>Mon, 27 Jul 2015 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Birdie]]></category>
		<category><![CDATA[Carlos M. Correa]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Joseph E. Stiglitz]]></category>
		<category><![CDATA[little]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Minister. Nirmala]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Nobel Laureates]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Sitharaman]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think Tank]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6867</guid>
		<description><![CDATA[Curiously enough, what a little birdie told me just a couple of weeks ago, very similar to that I read in various media reports even less than a week later. It was related to a somewhat trepidatious national policy in the making on &#8230; <a href="http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Utility Model: Would It Work In India For Pharma?</title>
		<link>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=utility-model-would-it-work-in-india-for-pharma</link>
		<comments>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/#comments</comments>
		<pubDate>Mon, 08 Jun 2015 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Biogen]]></category>
		<category><![CDATA[dimethyl]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Forward Pharma A/S]]></category>
		<category><![CDATA[fumarate]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tecfidera]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[Utility]]></category>
		<category><![CDATA[Utility Model]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6704</guid>
		<description><![CDATA[The revised draft of India&#8217;s IPR Policy penned by the Government constituted ‘Think-Tank’ in 2014, suggests enactment of new laws, such as for ‘Utility Models’ and Trade Secrets, to fill some gaps in the country&#8217;s IPR ecosystem . However, media reports &#8230; <a href="http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TPP: Discord Within A Strange Mélange And Impact On Access To Medicines</title>
		<link>http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines</link>
		<comments>http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/#comments</comments>
		<pubDate>Mon, 25 May 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[access to medicines]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[Asia-Pacific]]></category>
		<category><![CDATA[democrats]]></category>
		<category><![CDATA[discord]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[geopolitical]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mélange]]></category>
		<category><![CDATA[Pacific]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TPP]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[Trans]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WikiLeaks]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6665</guid>
		<description><![CDATA[On May 19, 2015, Bloomberg reported that a sizable number of President Barack Obama’s own party colleagues, besides teachers, seniors, Internet freedom groups and nuns, have joined the push to defeat the proposed Trans-Pacific Partnership (TPP) treaty. Before I delve into the TPP, &#8230; <a href="http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Curious Imbroglio: Innovation, IPR, India and ‘Uncle Sam’</title>
		<link>http://www.tapanray.in/the-curious-imbroglio-innovation-ipr-india-and-uncle-sam/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-imbroglio-innovation-ipr-india-and-uncle-sam</link>
		<comments>http://www.tapanray.in/the-curious-imbroglio-innovation-ipr-india-and-uncle-sam/#comments</comments>
		<pubDate>Mon, 04 May 2015 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[Ayog]]></category>
		<category><![CDATA[bullying]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[imbroglio]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime Minister]]></category>
		<category><![CDATA[priority watch list]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Special 301]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think Tank]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Uncle Sam]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6572</guid>
		<description><![CDATA[Last week, the Office of the United States Trade Representative (USTR) released the “2015 Special 301 Report”, which is its annual review of the global state of Intellectual Property Rights (IPR) protection and enforcement. While looking through the Kaleidoscope of &#8230; <a href="http://www.tapanray.in/the-curious-imbroglio-innovation-ipr-india-and-uncle-sam/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-imbroglio-innovation-ipr-india-and-uncle-sam/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Data Protection’: Needs A Clear Direction…But Is It An IPR Issue?</title>
		<link>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue</link>
		<comments>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/#comments</comments>
		<pubDate>Mon, 02 Mar 2015 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[39.3]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Charles]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Clift]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Satwant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6397</guid>
		<description><![CDATA[The terminologies ‘Data Exclusivity’ and ‘Data Protection’ are quite often used interchangeably by many, creating a great deal of confusion on the subject. However, in a true sense these are quite different issues having critical impact on public health interest &#8230; <a href="http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Patent Linkage’: Can The Core Issue Be Resolved?</title>
		<link>http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-linkage-can-the-core-issue-be-resolved</link>
		<comments>http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/#comments</comments>
		<pubDate>Mon, 23 Feb 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[administrative]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Arun]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[Corporation]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Froman]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Jaitley]]></category>
		<category><![CDATA[Kher]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[measures]]></category>
		<category><![CDATA[Mike]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pratibha]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[rajiv]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[RTI]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[visit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6392</guid>
		<description><![CDATA[On February 10, 2015, a leading business daily of India, quoted the Commerce Secretary of India &#8211; Rajeev Kher, saying, “India needs to relook at its Intellectual Property Rights (IPR) Policy with a view to bring in a differentiated regime &#8230; <a href="http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reverberations Around The Proposed New IPR Policy Of India</title>
		<link>http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reverberations-around-the-proposed-new-ipr-policy-of-india</link>
		<comments>http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/#comments</comments>
		<pubDate>Mon, 16 Feb 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Arjun Jayadev]]></category>
		<category><![CDATA[Barack]]></category>
		<category><![CDATA[Dean Baker]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Joseph E. Stiglitz]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[Narendra]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[World Trade Organization (WTO)]]></category>
		<category><![CDATA[‘Project Syndicate’]]></category>
		<category><![CDATA[‘The World Opinion Page’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6381</guid>
		<description><![CDATA[“If the Obama administration succeeds in forcing India to strengthen its patent laws, the change would harm not only India and other developing countries; it would also enshrine a grossly corrupt and inefficient patent system in the US, in which &#8230; <a href="http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What President Obama And Prime Minister Modi Discussed On IPR And Healthcare In India</title>
		<link>http://www.tapanray.in/what-president-obama-and-prime-minister-modi-discussed-on-ipr-and-healthcare-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-president-obama-and-prime-minister-modi-discussed-on-ipr-and-healthcare-in-india</link>
		<comments>http://www.tapanray.in/what-president-obama-and-prime-minister-modi-discussed-on-ipr-and-healthcare-in-india/#comments</comments>
		<pubDate>Mon, 02 Feb 2015 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[Barack]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Froman]]></category>
		<category><![CDATA[GHSA]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[house]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[January]]></category>
		<category><![CDATA[joint statement]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Meeting]]></category>
		<category><![CDATA[Mike]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Narendra]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[representative]]></category>
		<category><![CDATA[section3.d]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[Summit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TPP]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[Trans-Pacific Partnership]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[white]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6358</guid>
		<description><![CDATA[During the recent visit of the US President Barack Obama to India from January 25-27, 2015, both the domestic and international media was abuzz with the speculation, whether or not India would concede some ground to America on the prevailing, generally &#8230; <a href="http://www.tapanray.in/what-president-obama-and-prime-minister-modi-discussed-on-ipr-and-healthcare-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-president-obama-and-prime-minister-modi-discussed-on-ipr-and-healthcare-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
